All News

drug2.holiday.jpg

Benefits vs Harms for Osteoporosis Drug Continuation or Discontinuation

d Jack Cush, MD

While it is clear that long-term bisphosphonate therapies reduce fracture risk in women with osteoporosis, it is unclear how to counter-balance these benefits against rare serious harms and how to optimize therapeutic benefits with appropriate drug holidays.

A systematic analysis of 48 studies compared long-term osteoporosis drug treatment (ODT) (>3 years) versus control versus ODT continuation versus durg discontinuation, to examine incident fractures or harms.

Read Article
Screen%20Shot%202019-06-12%20at%204.26.31%20PM.png

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

d Janet Pope, MD, MPH, FRCPC

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

Read Article
BP.jpg

Allopurinol Fails to Curtail Hypertension

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Read Article
IMG_2743.JPG (keep)

EULAR 2019 – Day 3 Report

d Jack Cush, MD

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

Read Article
US.hand_.jpg

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

d David Liew, FRACP

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rhe

Read Article
Metanalysis shows the prevalence of autoimmune hepatitis for Asian, European, and American populations was 12.99 (95% CI: 2.05–23.92), 19.44 (15.63–23.24), and 22.80 (13.48 to 59.07) per 100,000; higher rates seen in women and elderly https://t.co/OtvvWBvb3x

Links:

Dr. John Cush RheumNow ( View Tweet)

A nested case-control study of 120 SLE pts matched against 240 controls and showed the risk of serious infections was associated with serositis (OR 2.76), hematologic involvement (OR 2.53) and daily steroid (>7.5mg/d) use (OR, 2.53). https://t.co/5zqV9jsNq1

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey of 1000 customers of two adult-use cannabis retail stores in Colorado shows that 65% of adults use cannabis to relieve pain & 74% use it to promote sleep. Over 80% said that cannabis was very or extremely helpful for pain or sleep. https://t.co/euDm7yq7Rc

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Kevin Winthrop at #EULAR2019 during his infection lecture delivers the Pearl that Tofacitinib pts found to have Latent TB cannot take Rifampin - drug interaction w/ Tofa (lowers levels) https://t.co/LpoRbVC77J
Dr. John Cush RheumNow ( View Tweet)
Dr. Kevin Winthrop - Expert Advice on TB Testing and Treatment from #EULAR2019 https://t.co/Nz7oKiIjrm

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Gerd Burmester reviews the SEMIRA study that examines whether or not you should wean that 5mg Prednisone in your RA patients. #EULAR2019 https://t.co/Vk0salb8bX

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of high and low iris acid levels in a large cohort of gout patients shows high SUA associated with more comorbidities and CKD, more colchicine & indocin use. #EULAR2019 SAT0435 https://t.co/FvUU4Q6Ky9
Dr. John Cush RheumNow ( View Tweet)
Shingrix can be give to inflammatory arthritis pts? Collective report from the Brigham & Women’s Hospital looked at the safety of Shingrix given to 300 RA, PsA, etc patient without any reports of H.Zoster and a 4% rate of "flares". #EULAR2019 FRI0068 https://t.co/Wkx5V9vM8r https://t.co/kErMMU97tB

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis from the BSRBR ankylosing spondylitis registry of 2420 AS pts shows that HLA-B27 is associated with an increased risk of anterior uveitis but a decreased risk of psoriasis and IBD. #Eular2019 OP0262 https://t.co/jslLYkMr9Q
Dr. John Cush RheumNow ( View Tweet)
#Hyperuricemia (HUC) /#gout found to be associated with CVD in a cohort of 37,315 PsA patients. Investigators at Icahn Mt Sinai saw higher rates of Afib and HF (with preserved ejection fraction) in patients with hyperuricemia/gout vs those without. SAT0371 #EULAR2019 @RheumNow https://t.co/98B3JSFSnv
Gout Study Group GoutGroup ( View Tweet)
Good lessons from 22,607 RA patients from the UK CPRD: cataracts and glaucoma from pred are dose dependent, and even 1000mg cumulative dose is enough. That’s equivalent to three months PMR therapy for most #EULAR2019 SAT0592 @dr_rachelblack @CatherineL_Hill @earlyARA @RheumNow https://t.co/AJfBgLdHdb
David Liew drdavidliew ( View Tweet)
Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p

Links:

Dr. John Cush RheumNow ( View Tweet)

14 patient pilot study presented by Dr. Genovese; once daily vagal stimulation worked but 4 times daily did not! https://t.co/TUWr7fT7x3

Links:

Dr. John Cush RheumNow ( View Tweet)

FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. Small incremental response when dose is escalated, and radiographic progression is low. #eular2019 @RheumNow

Alberta Hoi tuna0sashimi ( View Tweet)

×